Product Facts
| Ticker Symbol | VWFBX |
| CUSIP | 89008T424 |
| Inception Date | April 28, 2025 |
| Dividends Paid |
Average Annual Total Returns %
As of June 30, 2025
As of June 30, 2025
| Most Recent Month End | YTD | 1 YR | 3 YR | 5 YR | 10 YR | Inception | Expense Ratios | |
|---|---|---|---|---|---|---|---|---|
| Gross | Net | |||||||
| Net Asset Value | — | — | — | — | — | +0.90 | 0.46% | 0.41% |
| With Sales Charge | — | — | — | — | — | -2.61 | ||
| Net Asset Value | — | — | — | — | — | +0.90 | 0.46% | 0.41% |
| With Sales Charge | — | — | — | — | — | -2.61 | ||
| Bloomberg U.S. Aggregate Bond Index | — | — | — | — | — | +1.02 | — | — |
| Bloomberg U.S. Aggregate Bond Index | — | — | — | — | — | +1.02 | — | — |
Inception Date - Class A: April 28, 2025
Current Maximum Sales Charge:
The performance quoted represents past performance and does not guarantee future results. Current performance may be lower or higher than the performance information shown. The investment return and principal value of an investment in the Portfolio will fluctuate, so that your shares, when redeemed, may be worth more or less than their original cost. See above "Average Annual Total Returns %" for performance information current to the most recent month-end.
Returns for the other share classes will vary due to different charges and expenses. Performance assumes reinvestment of distributions and does not account for taxes.
Total investment return at net asset value has been calculated assuming a purchase at net asset value at the beginning of the period and a sale at net asset value at the end of the period; and assumes reinvestment of dividends, capital gain distributions and return of capital distributions/allocations, if any, in accordance with the provisions of the dividend reinvestment plan. Net asset value equals total Fund assets net of Fund expenses such as operating costs and management fees. Total investment return at net asset value is not annualized for periods less than one year.
Past performance does not guarantee future results.